コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n were enrolled onto this single-institution phase I study.
2 antitumor activity were demonstrated in this phase I study.
3 nd gemcitabine has been evaluated in a prior phase I study.
4 therapy enrolled in this 28-day, open-label, phase I study.
5 /IV NSCLC were enrolled to this multicenter, phase I study.
6 previously entered at least one child into a phase I study.
7 d granulocyte-colony-stimulating factor in a phase I study.
8 Twenty-four patients were treated in the phase I study.
9 refractory solid tumors were enrolled onto a phase I study.
10 bstantial clinical activity was seen in this phase I study.
11 ified the process of dose escalation in this phase I study.
12 stinal graft-versus-host disease (GVHD) in a phase I study.
13 Eighteen patients are assessable on this phase I study.
14 an cancer patients that was noted during the phase I study.
15 afe, well tolerated, and immunogenic in this phase I study.
16 center, randomized, double-blind, controlled phase I study.
17 maximum-tolerated dose derived in a previous phase I study.
18 in a patient with ACC who was enrolled in a phase I study.
19 ent glioblastoma multiforme (GBM) in a prior phase I study.
20 ouble-blinded, placebo-controlled, crossover phase I study.
21 or activity in taxane-refractory patients in phase I studies.
22 ncer treated in two ongoing, dose-escalating phase I studies.
23 ( P =.01 and.004, respectively) was seen in phase I studies.
24 UC, SUV, and Cmax were observed in tumors in phase I studies.
25 l development, with the majority still being phase I studies.
26 and inflexible study designs of traditional Phase I studies.
27 mising candidate for evaluation in pediatric phase I studies.
28 riguing clinical safety and efficacy data in phase I studies.
29 double-blind, randomised, placebo-controlled phase I studies.
30 of FAPbI3 between the alpha-phase and delta-phase is studied.
32 ulticenter, double-blind, placebo-controlled phase I study, 13 subjects were randomized to single-dos
37 citabine has shown some promising results in phase I studies and is being investigated in phase II tr
38 PH-797804 has met safety criteria in human phase I studies and is under clinical development for se
40 clinical toxicology, human pharmacokinetics, phase I studies, and activity against gastric carcinoma
41 lete and partial responses were seen in this phase I study, and clinical response appears related to
48 e or a lot of pressure to participate in the phase I study because their cancer was growing, whereas
52 he Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose o
64 sed therapy, three of whom were treated in a phase I study designed to establish the maximum tolerate
68 made one of three decisions (enrollment on a phase I study, do not resuscitate status, or terminal ca
84 linositol 3-kinase-delta, was evaluated in a phase I study in 64 patients with relapsed indolent non-
87 controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoria
89 m an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multic
90 lticenter, double-blind, placebo-controlled, phase I study included adults who had been maintained on
95 ly by an overall reduction in recruitment to phase I studies of 20%, more than half of whom would in
97 A criteria have routinely been enrolled onto phase I studies of antineoplastics without clinically me
98 dynamic biomarkers in cancer patients in two phase I studies of MLN8054, a small-molecule inhibitor o
101 sistent with previously reported values from phase I studies of the drug given as a 24-hour IV infusi
103 aneously) on mast cells and melanocytes in a phase I study of 10 patients with advanced breast carcin
105 d radiation dose estimates of this tracer, a Phase I study of 62Cu-PTSM was performed using whole-bod
110 ising results have been reported in an adult phase I study of ABT-510, a peptide derivative of the na
112 Early observations of clinical benefit in a phase I study of cabozantinib, which included patients w
113 siency for this upregulation, we performed a phase I study of capecitabine in combination with weekly
115 mporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) le
116 patients with advanced melanoma treated in a phase I study of dose escalation of vemurafenib (PLX06-0
127 ies that required RT were enrolled onto this phase I study of standard chest radiation (30 daily 2-Gy
132 edly with prolonged exposure, we performed a phase I study of weekly XR5000 by 120-hour continuous in
134 or currently under investigation in multiple phase I studies on various malignancies, and its clincal
135 ated clinically relevant improvement in this phase I study on this small group of patients with activ
139 1.46 L x min(-1) x m(-2) in pre-phase I and phase I studies, respectively) with the production of se
147 bial activity, and clinical response in this Phase I study suggest that this tetracycline-containing
158 cademia often partner for the performance of phase I studies, their administrative processes are gene
160 conducted a first-in-man (to our knowledge) phase I study to determine the dose-limiting toxicities
193 afenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study
195 Serum levels of flavopiridol obtained during phase I studies were sufficient to inhibit in vitro canc
198 inal illnesses who enroll as participants in phase I studies, which assess the toxicity and dosing of
199 teria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic
202 ificantly decrease the duration of pediatric phase I studies without increasing the risk of toxicity.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。